Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 + toripalimab vs paclitaxel in CCR8-positive advanced gastric/GEJ adenocarcinoma
CTR20260090Phase 3Active
- Sponsor
- LaNova Medicines
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of LM-108, toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by LaNova Medicines. Started Apr 2026; status: active.
02
Drugs
LM-108toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260090.